Tetra Natural Health Announces The Arrival of 20 containers of Hemp Energy Drink in Canada
Momentum Public Relations
Press Release: April 30, 2019
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made from hemp in the country. In the coming weeks, Tetra Natural Health will be in a position to supply the entire country from its distribution centres in Montreal (for the Quebec and Maritimes market), Toronto (for the Ontario and central Canada market) and Vancouver (for the Western Canada market).
Since the beginning of the year, Hemp Energy Drink (www.hempenergydrink.ca) has been available in many stores across Western Canada. Consumers have greatly appreciated this refreshing, low-calorie beverage with many natural ingredients that comes in three flavours: classic, mango and raspberry.
“We’re delighted that large quantities of Hemp Energy Drink have finally arrived and look forward to Canadian consumers getting a chance to have easy access to and taste this unique and refreshing beverage,” said Richard Giguère, CEO of Tetra Natural Health. “We thank Canadians for their patience, which will soon be rewarded since Hemp Energy Drink will be available in many stores across the country”.
A photo accompanying this announcement is available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/a82073ce-d298-49bb-a39e-140f169ed893
About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information: www.tetranaturalhealth.com
About Tetra Bio-Pharma
Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information, visitez: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For more information, please contact:
Richard Giguère
CEO
Tetra Natural Health
W. 348-899-7575 ext. 210
rgiguere@tetranaturalhealth.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development
Momentum Public Relations
Press Release: April 29, 2019
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
The Joint-Venture will synergize the capabilities of the two companies:
- Products: The companies have identified product candidates in the fields of pain, oncology and ophthalmology, addressing a total market size of over $10BN. (Source: MedTrack™)
- New Routes of Administration: Altus’ SmartCelle™ insoluble drug delivery platform enables intravenous, topical, intra-nasal and oral delivery. Smartcelle’s™ proven ability to enhance the solubility of cannabinoids permits increased oral absorption and enables low volume parenteral and transmucosal delivery. Intellitab™ and Flexitab™ technologies will deliver Safer to Use™ products to patients.
- New Intellectual Property: Altus’ distinct drug delivery technologies provide Tetra with significant strategic advantages over the competition and will enable Tetra to significantly improve some of the current products under development. In addition to SmartCelle™ these include Intellitab™ abuse deterrent technology platform and, Flexitab™ breakable sustained release tablet technology for enhanced dosing flexibility. All platforms are protected by patents enforced globally.
- Commercial Development, Manufacturing and Supply. Combining Altus and Tetra capabilities ensures these essential parts of the value chain are addressed early and efficiently.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are extremely excited about finalizing this agreement which will enable us to improve existing products and will allow us to exploit a number of different delivery mechanisms including Intra-Nasal, Intravenous and Oral Sustained Release Tablets. Furthermore, Altus’ technology will play a key role in strengthening Tetra’s Intellectual Property for its product portfolio. This newly created joint-venture will also serve to benefit our patients, their care providers and help us in our quest to replace the use of opioids.”
Damon Smith President and CEO of Altus Formulations Inc. added, “We believe that by targeting cannabinoid receptors we open up a range of therapeutic pathways unaddressed by today’s medications. Whether alone or in combination, we believe such medications can provide great value to patients, not least to those suffering the blight of undertreated pain. By combining our capabilities and focusing our resources to generate the right drug for the right patient, the Tetra/Altus joint venture overcomes many of the hurdles that have dogged cannabinoid medicine commercialization in the past. We greatly look forward to working with the Tetra team and to bringing these products to the market.
About Altus Formulation Inc.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost-effective new products for its partners and their patients. With a focus on Safer to Use™ formulations, Altus’ technologies include Intellitab™ abuse deterrent technology, Flexitab™ breakable extended release tablets and SmartCelle™ technologies for delivery of low solubility large and small molecules.
For more information, please visit www.altusformulation.com
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Contact:
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Grown Rogue Announces Proposed Acquisition of Decibel Farms, Inc.
Momentum Public Relations
Press Release: April 24, 2019
Grown Rogue International Inc. (CSE:GRIN | OTC: NVSIF) (“Grown Rogue” or the “Company”), a vertically-integrated, multi-state cannabis company, and Decibel Farms, Inc. (“Decibel”), a fully organic and sustainable producer and processor of fine cannabis products in southern Oregon, have executed a binding letter of intent (the “LOI“) which sets out the general terms and conditions pursuant to which Grown Rogue will acquire the assets, including real estate, intellectual property and other assets of Decibel for aggregate consideration of USD$3,000,000, subject to adjustment as described below (the “Transaction”).
Decibel is a family owned and operated, 5-acre sungrown and greenhouse farm located in the Applegate Valley in the heart of Southern Oregon with a 2,500 square foot processing center in Medford, Oregon. Decibel owners Shawn Bishop and Buddy Wilson are veterans of cannabis cultivation. Over the past 3 years, Decibel has built a truly sustainable cultivation facility that utilizes biological cultivation practices and has garnered several prestigious quality awards including:
- 1st place sungrown flower Oregon Growers Cup 2017
- 2nd place Infused Pre-roll Dope Cup 2018
- 3rd Place Sungrown Flower 2018 Oregon Growers Cup
- 2nd Place Solventless Extract 2018 Oregon Growers Cup
In addition to award winning flower, Decibel also distributes award winning infused pre-rolls called “Decibel Louds” and award winning solventless extracts called “Decibel Dabs”. All Decibel products are inline with the company’s primary ethos of clean and responsible cannabis which is in alignment with Grown Rogue’s high standards for sustainable cultivation and environmentally responsible packaging.
Obie Strickler, CEO of Grown Rogue, explained the value of the acquisition stating, “Grown Rogue is continuing to see significant month over month sales growth, such that demand for our award winning products is surpassing our current capacity to deliver in Oregon. This acquisition addresses this demand by immediately adding Decibel’s inventory valued at more than US$1 million wholesale to Grown Rogue’s supply. The acquisition also adds another well respected brand into the Grown Rogue portfolio of brands, enabling us to continue growing our market share. Decibel will expedite our ability to ramp up product supply by adding Decibel’s 40,000 sq ft cultivation and manufacturing capacity, as well as a very experienced management to the Grown Rogue leadership team.”
Upon closing of the Transaction Shawn Bishop will be appointed Vice President of Manufacturing for Grown Rogue and Buddy Wilson will lead Grown Rogue’s sales team as Vice President of Sales.
“Merging operations with Grown Rogue is an incredible opportunity for both companies,” said Shawn Bishop, founder and CEO of Decibel. “We’re very excited to be joining such a skillful and like-minded team with the ability to scale our collective efforts into many other states and markets. The thoughtful approach to strategic expansion demonstrated by Obie and his team inspires great confidence.”
Mr. Strickler added, “There are very good synergies between our teams. Together we are much more capable to extend the proven, vertically integrated platform into additional regions.”
Terms of the Transaction
The Transaction will be structured as a tax-free merger, pursuant to which Decibel will merge with and into Grown Rogue Gardens, LLC, a wholly-owned indirect subsidiary of the Company pending final due diligence and a definitive merger agreement (the “Definitive Agreement“). The real estate property of Decibel will be acquired by GRU Properties, LLC, a wholly-owned indirect subsidiary of the Company, pursuant to a customary commercial real estate acquisition agreement.
The consideration to be paid to the shareholders of Decibel shall consist of: (i) USD$2,000,000 of common shares of the Company, to be issued twelve months from the signing of the Definitive Agreement with respect to the Transaction, with the number of shares to be issued to be determined based on the volume weighted average price of the Company’s common shares as reported by the Canadian Securities Exchange (the “CSE“) for the ten trading days immediately prior to the date that is twelve months from the closing date, up to a maximum of C$1.25 per share; and (ii) up to an additional USD$1,000,000 of common shares on the same terms based on the completion of certain business and operational milestones achieved by the Company. The issuance of the Company’s common shares under the Transaction is subject to compliance with applicable securities laws and the policies of the CSE.
“The terms of this all stock purchase, with share price to be set 12 months out, limits current dilution to our existing shareholders while increasing capacity for product growth and revenue generation. These mandates have been fundamental to our company’s vision to develop strong investor relationships that provide measurable returns,” added Mr. Strickler.
The closing of the Transaction will be subject to, among other things, satisfactory completion of due diligence by the Company, regulatory approvals, and delivery of a definitive merger agreement and other related transaction documents by June 30, 2019.
About Grown Rogue
Grown Rogue International (CSE: GRIN | OTC: NVSIF) is a vertically-integrated, multi-state cannabis company curating innovative products to provide consumers with the right cannabis experience. Each of Grown Rogue’s products and strains are categorized and marketed based on unique effects and designed for the full range of a consumer’s lifestyle. Grown Rogue is scaling the vertically integrated model into multiple states by incorporating best-in-class manufacturing facilities and a proprietary distribution platform based on Microsoft technology. Grown Rogue’s diverse cannabis product suite includes premium flower, patent-pending nitrogen sealed pre-rolls, oil and concentrates, and edibles featuring a partnership with world-renowned chocolatier, Jeff Shepherd.
- Published in Cannabis, Grown Rogue, Marijuana, News Home
CROPs 57,600 Square Foot Nevada Nursery Ready for Plants for CBD Farms
Momentum Public Relations
Press Release: April 23, 2019
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it has completed the construction of its 57,600 square foot nursery in Nye County, Nevada.
It has been equipped with trays and LED lighting specially designed to enhance the growth of plant starts for the 2019 CBD farms licenced on the company’s various properties in the state. This was a key project in order to maximize yield, reduce farming risk and costs for the 2019 planting season.
CROP continues to gauge interest and review potential off take relationships for the 2019 season for its CBD products.
The global medical cannabis market value is expected to reach a value of US$ 45.4 Billion by 2024, with a CAGR of 22.9% during 2019-2024, according to IMARC research. The firm’s estimate for last year was that it would to reach US$ 13.4 Billion.
CROP CEO, Michael Yorke, stated: “The CROP family of companies and subsidiaries continues to build strategic infrastructure in key states where we are present. These are one time builds that will streamline harvests, reduce risks and costs as well as maximize yields for many years to come.”
“We are very proud of our team members for putting in the extra hours to ensure the season ahead is as successful and profitable as can be. We are encouraged by the number of interested parties in the products we are producing and will look to secure long term reliable relationships to the benefit of stakeholders and the company’s farming, marketing and construction divisions.”
About CROP
CROP is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Nevada Project; the technological effects of Nevada Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604)484-4206
- Published in Cannabis, CROP Infrastructure, Marijuana, News Home
CROP California Receives 1,000 Four Foot Cannabis Plants to Begin and Accelerate the 2019 California Cultivation Season
Momentum Public Relations
Press Release: April 18, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that its 49% owned Humboldt County farm has received an order of 1,000 4 ft. tall cannabis plants accelerating the company and its farm in to the 2019 cultivation season.
These large starter plants are expected to have increased yields as they are much taller and fuller than the previous years plants. Currently, the farm has five 2,000 sq.ft. greenhouses totaling 10,000 square feet and 20,000 square feet of outdoor cultivation space.
Additionally, the farm has received approval from the Humboldt County Planning Department for the 2019 expansion, including a 30,000 sq. ft. automated light dep greenhouse facility and additional vault space. The new facility is expected to cost $499,000 in capex at the farm and is expected to yield 12,000 pounds per year, taking the company to year-round cultivation and tripling the output of the existing Californiainfrastructure.
CROP’s Emerald Heights retail brand has had its licensing fees submitted for phase two of Chula Vista’scannabis retail application process, combined with the company’s partial acquisition of a distributer and extraction facility, if licenced the retail location will bring the company to being fully vertically integrated.
A report from cannabis industry research firm BDS Analytics predicts that the California cannabis market will increase to $5.1 Billion in 2019 as more dispensaries come online. Analysts at Cowen & Co. believe the nation’s legal cannabis industry could reach $50 billion by 2026, with California accounting for about $25 billion of that market, according to CFN Media Group.
CROP CEO, Michael Yorke, stated: “The company’s manufacturing partners are finishing up the farms final products of the 2018 season and now we are preparing to scale up our operations with a new state of the art facility. We will be particularly interested to see how these new, advanced plants perform.”
About CROP
Crop is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Oklahoma Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: +1(604) 484-4206
- Published in Cannabis, CROP Infrastructure, Marijuana, News Home
Crop to Enter Oklahoma Medical Cannabis Market
Momentum Public Relations
Press Release: April 17, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it has identified multiple Tenants for a roll out strategy to enter Oklahoma to target the Medical Cannabis market focusing on Cultivation, Extraction and Retail infrastructure. CROP will own 49% of the newly incorporated company.
The focus of the Oklahoma partnership will be to set up 20 acres of cultivation for medical cannabis and establish up to three retail locations. The 20 acres of medical Cannabis, once tenants are cultivating, is estimated to yield 30,000 lbs of dried flower per year. CROP has agreed to fund up to $500,000 USD for the initial start-up capital for the cultivation and retail locations.
In November 2018, an effort to place recreational cannabis on Oklahoma’s ballot fell short by 20,000 signatures. The Secretary of State’s office determined supporters of the initiative gathered only about 103,000 signatures for State Question 797. The required 123,000 signatures was not met to qualify for a public vote.
After three to five years, according to the Marijuana Business Factbook 2018, annual dispensary sales in Oklahoma are expected to generate up to $250 millionfrom medical cannabis.
The global medical cannabis market value is expected to reach a value of US$ 45.4 Billion by 2024, exhibiting a CAGR of 22.9% during 2019-2024, according to IMARC research. The firm’s estimate for last year was that it would to reach US$ 13.4 Billion.
CROP CEO, Michael Yorke, stated: “This is the 4th state where the company and its brands now have a presence. Medical cannabis is the sweet spot in this business with, potentially, very high returns on investment, so we see this as another very significant step forward in CROP’s US-focused roll-out strategy.”
About CROP
Crop is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Oklahoma Project; the technological effects of Oklahoma Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: +1(604) 484-4206
- Published in Cannabis, CROP Infrastructure, Marijuana, News Home
ARCTIC ACQUIRES SECOND EXPLORATION PERMIT, “VAIMOSOU”, TIMANTTI PROJECT FINLAND
Momentum Public Relations
Press Release: April 16, 2019
Arctic Star Exploration Corp. has successfully applied for and received its second exploration permit totalling 882 hectares, named Vaimosou, on its 100-per-cent-owned Timantti project near Kuusamo, Finland. The permit adjoins and partially surrounds the existing 289-hectare exploration permit named Salvarra which contains all of the company’s kimberlite discoveries to date. Vaimosou falls within the company’s exploration reservation totalling 193,700 hectares. A drone/UAV-based (unmanned aerial vehicle) magnetic survey was completed over the new permit last year and revealed three primary high-priority pipe-like targets. The magnetic survey also covered the western portion of the Wolf kimberlite trend which is expressed as a series of magnetic anomalies stretching 1.8 kilometres, of which the most eastern 300 metres are the Wolves themselves. Permission to access these targets from the surface rights owners is now being sought, and exploration will begin with ground geophysical surveys.
Arctic Star now has a total 1,171 hectares of exploration permits and plans to continue to add to this as warranted by the company’s regional exploration work.
Qualified person
The technical data in this news release has been reviewed and approved by Buddy Doyle, a diamond geologist with over 30 years of experience, a qualified person under the provisions of National Instrument 43-101.
About Arctic Star Exploration Corp.
The company owns 100 per cent of the recently acquired Timantti diamond project, including a 243 ha exploration permit and a 193,700 ha exploration reservation near the town of Kuusamo in Finland. The project is located approximately 550 km southwest of the operating Grib diamond mine in Russia. Arctic has commenced its exploration in Finland on the Timantti project, where four diamondiferous kimberlite bodies may represent the first finds in a large kimberlite field. The company also controls diamond exploration properties in Nunavut (Stein) and the Northwest Territories (Diagras and Redemption).
We seek Safe Harbor.
- Published in Arctic Star Exploration, Mining, News Home
Nass Valley Confirms its New CEO as President and Issues Incentive Stock Options
Momentum Public Relations
Press Release: April 15, 2019
Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”), wishes to announce that at its Board of Directors (“BoD”) meeting held on April 10, 2019 the BoD has confirmed its new CEO, Mr. John Peter Affenita as President and CEO of the Company. The Company also established a Corporate Governance & Environment Committee consisting of three initial members which will be nominated and appointed during its next BoD meeting.
The Company is also pleased to announce that stock options have been granted to Directors, Officers, Committee Members and Consultants of the Company including its subsidiaries, to purchase up to an aggregate of 1,555,000 common shares of the Company. The stock options will be exercisable at a price of $0.18 per share with expiration date of April 10, 2022.
About Nass Valley
Nass Valley Gateway (CSE: “NVG”; Frankfurt: “3NVN”) is a diversified healthcare company which is focused to further expand the business of its acquired subsidiary Pro-Thotics Technology Inc. (“PTI”) which was established in 1988. The Company is increasing its marketing of durable medical equipment products (DME-Business) on a national level, to encompass all states of the USA and other areas of North America and is aggressively developing the marketing, production and vertical integration of Cannabidiol (CBD) products without Tetrahydrocannabinol (“THC”) content for internal use including CBD infused skin, bath, and body care products of its wholly owned subsidiary Advanced Bioceuticals Limited (“ABL”).
PTI is licensed to supply its products also to Medicare patients in the US and has established, over its more than 25 -year history, a database of more than 200,000 patients, located throughout the U.S. and Puerto Rico, who were seeking wellness from pain relief.
Through its subsidiary ABL, Nass Valley is determined to expand upon this pain relief concept tof its ABL-Business and to aggressively focus on the hemp based CBD marketplace with a global market of $3.1 billion (New Frontier Data) and expand its current New Jerseyoperations internationally.
We seek Safe Harbor.
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.
SOURCE Nass Valley Gateway Ltd.
View original content: http://www.newswire.ca/en/releases/archive/April2019/15/c7864.html
- Published in CBD, Nass Valley Gateway, News Home